The Infiltrator: Recognizing Cardiac Amyloidosis on Echo

Key Takeaways

• Up to 25% of >80-year-olds have amyloid at autopsy
• Thickened ventricular walls with sparkling appearance suggest amyloid
• Restrictive filling patterns indicate diastolic dysfunction
• Apical sparing on strain imaging is highly specific

Summary

Cardiac amyloidosis affects up to a quarter of people over 80 yet remains largely undiagnosed. Characteristic echocardiographic signs—including thickened walls, restrictive filling patterns, and the apical‑sparing strain signature—allow clinicians to suspect the disease early. Differentiating the three amyloid subtypes on echo guides targeted, disease‑modifying therapy. Prompt identification therefore shifts patients from a silent trajectory to actionable treatment pathways.

Pulse Analysis

Cardiac amyloidosis, once considered a rare autopsy finding, is now recognized as a prevalent condition in the aging population. Autopsy studies reveal that roughly one in four individuals over eighty harbor amyloid deposits in the myocardium, yet most never receive a clinical diagnosis. This gap stems from the disease’s insidious presentation and the historical reliance on invasive biopsy. Modern echocardiography, however, offers a non‑invasive window into myocardial architecture, allowing clinicians to spot subtle clues before irreversible damage sets in.

Two‑dimensional echo provides the first visual hints: concentric left‑ventricular wall thickening that appears “sparkling” or granular, often accompanied by small pericardial effusions. Doppler interrogation uncovers a restrictive filling pattern—elevated E‑wave velocity, shortened deceleration time, and reduced tissue‑Doppler e' velocities—signaling stiff ventricles. The most discriminating marker is the apical‑sparing pattern on speckle‑tracking strain imaging, where basal segments show markedly reduced longitudinal strain while apical segments are relatively preserved. This bull’s‑eye appearance distinguishes amyloid from other hypertrophic processes and helps differentiate light‑chain, transthyretin wild‑type, and mutant subtypes.

The therapeutic landscape has shifted dramatically with the advent of disease‑modifying agents such as tafamidis for transthyretin amyloidosis and novel monoclonal antibodies targeting light‑chain deposits. Early echo‑driven diagnosis positions patients to receive these therapies before extensive fibrosis ensues, translating into lower hospitalization rates and extended survival. Consequently, professional societies now advocate routine echo screening in elderly patients with unexplained heart failure, increased wall thickness, or atrial arrhythmias. Ongoing research aims to refine strain thresholds and integrate artificial‑intelligence algorithms, promising even earlier detection and personalized treatment pathways.